The present review aimed to establish an understanding of the pathophysiology of
leptomeningeal disease as it relates to late-stage development among different cancer …

From a historic lens, treatment for patients with relapsed/refractory multiple myeloma (R/R
MM) has advanced significantly since the advent of immunomodulatory agents (IMiDs) in the …

Acute kidney injury (AKI) is not only a worldwide problem with a cruel hospital mortality rate
but also an independent risk factor for chronic kidney disease and a promoting factor for its …

Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with
carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA …

CANDOR (NCT03158688) is a phase 3, randomized, open-label trial comparing carfilzomib,
daratumumab, and dexamethasone (KdD) vs carfilzomib and dexamethasone (Kd) in adults …

Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and
extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM …

Abstract N 6‐Methyladenosine (m6A) is an important RNA modification catalyzed by
methyltransferase‐like 3 (METTL3) and METTL14. m6A homeostasis mediated by the …

The therapeutic landscape in multiple myeloma (MM) has changed dramatically over the last
2 decades. With the introduction of novel immunotherapies, patients with MM can expect …

There are disparities in outcomes for patients with multiple myeloma (MM). We evaluated the
influence of sociodemographic factors on global disparities in outcomes for patients with …

Dracocephalum moldavica, known as Xiang-qing-lan (in Chinese), is a traditional folk
medicine, which was commonly used by Mongolian and Xinjiang Uyghurs area …